OTCMIVRN
Market cap0kUSD
Dec 06, Last price
0.00USD
Name
H-Cyte Inc
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
72.67%
Rev. gr., 5y
16.94%
Revenues
453k
-71.86%
Net income
-15m
L+194.38%
CFO
-2m
L-60.21%
Profile
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | |||||||||
Revenues | 453 -71.86% | 1,612 -25.07% | |||||||
Cost of revenue | 3,511 | 6,804 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (3,058) | (5,193) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 4,244 | 141 | |||||||
Tax Rate | |||||||||
NOPAT | (7,302) | (5,334) | |||||||
Net income | (14,543) 194.38% | (4,940) -36.95% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 402 | 383,694 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 3,923 | 3,556 | |||||||
Long-term debt | 1,760 | 220 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 321 | ||||||||
Net debt | 7,597 | 3,681 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (1,914) | (4,810) | |||||||
CAPEX | (8) | ||||||||
Cash from investing activities | 469 | (8) | |||||||
Cash from financing activities | 1,818 | 3,272 | |||||||
FCF | (3,058) | (4,064) | |||||||
| Balance | |||||||||
Cash | (1,914) | 95 | |||||||
Long term investments | |||||||||
Excess cash | 15 | ||||||||
Stockholders' equity | (58,889) | (48,362) | |||||||
Invested Capital | 55,472 | 47,318 | |||||||
ROIC | |||||||||
ROCE | 89.50% | 497.42% | |||||||
| EV | |||||||||
Common stock shares outstanding | 294 | 146 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (3,044) | (5,177) | |||||||
EV/EBITDA | |||||||||
Interest | 368 | 177 | |||||||
Interest/NOPBT | |||||||||